High-dose cyclophosphamide (Cy) and G-CSF are widely used to mobilize hematopoietic stem cells (HSC) for treating patients with high dose chemotherapy and autologous stem cell transplantation (ASCT). As lymphocyte count in the graft collected after Cy-G-CSF treatment is an independent survival factor after ASCT for patients with multiple myeloma (MM), our purpose was to study how Cy-G-CSF treatment affects the phenotype and function 
Abstract
High-dose cyclophosphamide (Cy) and G-CSF are widely used to mobilize hematopoietic stem cells (HSC) for treating patients with high dose chemotherapy and autologous stem cell transplantation (ASCT). As lymphocyte count in the graft collected after Cy-G-CSF treatment is an independent survival factor after ASCT for patients with multiple myeloma (MM), our purpose was to study how Cy-G-CSF treatment affects the phenotype and function of T cells in patients with MM. Cy induced a threefold decrease of T-cell counts with a slow and partial T-cell recovery of one-third at the time of HSC collection. Cy-G-CSF treatment did not affect the relative ratios of central memory, effector memory, and late effector CD4 + or CD8 + T cells, but a decrease in the percentage of naive CD4 + cells was observed. The percentages of CD25 + cells increased two-to threefold in CD4 + and CD8 + T cells, the former including both activated CD25 low and CD25 high cells. CD4
Introduction
High-dose chemotherapy (HDC) associated with autologous stem cell transplantation (ASCT) improves the rate of complete remission and overall survival in patients with multiple myeloma (MM) and non-Hodgkin lymphoma at relapse (1, 2) . Many studies have focused on the efficient mobilization of hematopoietic stem cells (HSC) by administration of hematopoietic growth factors with or without high-dose cyclophosphamide (Cy) (3) (4) (5) (6) (7) (8) . Cy induces profound aplasia with the production of endogenous mediators and growth factors that favor hematopoietic recovery. These endogenous mediators and the administrated recombinant granulocyte colony-stimulating factor (G-CSF) stimulate HSC proliferation and their mobilization into the peripheral blood. This mobilization is attributable to the activation of bone marrow neutrophils by hematopoietic growth factors, in particular G-CSF, resulting in the production of enzymes which cleave adhesion molecules and chemokines and in the release of HSC from the bone marrow environment (9, 10) . Because T lymphocytes are major actors in the graft-versus-host reaction in allogenic HSC transplantation, the characteristics of T lymphocytes collected by leukapheresis after HSC mobilization with G-CSF have been analyzed. Some studies indicate that G-CSF doubles the circulating T lymphocyte rate without major changes in the phenotype of T cells (11, 12) . Several other studies (13) (14) (15) demonstrate that G-CSF might affect the cytotoxic T-cell activity by inducing human lymphocytes to preferentially release type 2 cytokines (IL-4, IL-5, and IL-10) rather than type 1 (IFNγ, TNFα and IL-2) upon activation. However, the phenotype and function of T lymphocytes mobilized with Cy and G-CSF have not been studied yet. This is important because Cy is a strong immunosuppressor. In mice, the Cy-induced immunosuppression is followed by a rapid T-cell repopulation, likely associated with the production of endogenous T-cell growth factors (16) . In addition, a selective toxicity of Cy on regulatory T cells (Treg) has been demonstrated (17) (18) (19) . Treg are CD4 + CD25 + T cells that control key aspects of tolerance to self-antigens by suppressing activation of naïve T cells and they are crucial in the prevention of autoimmune diseases (20, 21) . Treg express a specific transcription factor, FOXP3, which controls both their development and function (22) . They also constitutively express some molecules associated with T-cell activation including GITR and CTLA-4 (23, 24) . Because a part of tumor-associated antigens is derived from self-antigens, Treg may be partially responsible for the lack of anti-tumor immune responses. In animal models, Treg expansion in the lymphoid organs of tumor-bearing animals is correlated with tumor volume, and the removal of Treg enhances anti-tumor immune responses. In humans, the proportion of Treg is increased in cancer patients. Thus, the depletion of Treg could be useful to promote an anti-tumor T-cell response (20, 21) .
A recent study has emphasized that the number of infused autologous lymphocytes collected by Cy and hematopoietic growth factor mobilization was an independent factor for overall survival and time to progression post HDC and ASCT, in patients with MM (25) . Given the lack of data regarding the phenotype and function of T lymphocytes in the HSC graft, the aim of our study was to characterize the behaviour of T-cell subpopulations after Cy-G-CSF treatment, and in particular that of Treg. Human CD4 + or CD8 + T cells can be classified into naïve T cells, central memory T cells, effector memory T cells, and late effector T cells (26, 27 We investigated here the phenotype and function of T lymphocytes present in the peripheral blood after high-dose Cy-induced aplasia and G-CSF mobilization in 14 patients with multiple myeloma. values were measured for beta-2-microglobulin (β2m) and the genes of interest during the log phase of the cycle. The expression levels of genes of interest were normalized to that of β2m
Materials and Methods

Patients and collection of peripheral blood samples
for each sample (δCt = Ct gene of interest -Ct β2m) and compared with the values obtained for a CD4 + CD25 high positive control isolated from a healthy donor, using the following formula: 100/2 δδCt where δδCt = δCt unknown -δCt positive control.
Treg suppression assay
Mature dendritic cells (DCs) were generated as detailed previously (29 
Results
Mobilization of T and NK lymphocytes
T-cell and NK-cell subpopulations profiles were studied for fourteen patients. Mean white blood cell (WBC) count dropped on day 6 following Cy administration and then increased due to G-CSF injection (Fig. 1A) . The mean WBC count was 10 × 10 9 /L on the day of the first leukapheresis procedure (median day 10, range: 9-12). G-CSF injections were stopped after HSC collection. Cy induced a sevenfold reduction of the CD3 + cell count on day 6
followed by a slow and partial recovery in all 14 patients ( 
Mobilization of naïve, central memory, effector memory and late effector T cells
We studied the subpopulations of naïve CD4 2B ) and did not differ from those previously reported in healthy donors (respectively, 30%, 8%, 30% and 32%) (32) .
Regulatory and activated T cells
The proportions of CD4 + and CD8 + T cells that expressed CD25 increased throughout Cy-G- (Fig. 3B ). These mean percentages were significantly increased 2.0-and 2.9-fold respectively, compared to those observed before Cy-G-CSF treatment (P ≤ .01). In humans, CD4 + CD25 + cells contain both regulatory T cells that express high levels of CD25 (CD4 + CD25 high ) and activated non-regulatory CD4 + CD25 low cells (33) . These two populations could be found before but also after Cy-G-CSF treatment, suggesting that Treg are still present after Cy administration (Fig. 4A) 
Immune cell composition of leukapheresis products
In (25) . Patients receiving a high number of lymphocytes had higher response rates and lower relapse rates, resulting in improved survival. In particular, the autograft absolute lymphocyte count was an independent prognostic factor for overall survival and progression-free survival in MM patients (25) + subsets in patients with MM were similar to those previously described in healthy individuals. They remained stable throughout the partial T-cell recovery after Cy administration, except for a slight decrease in the naïve CD4 + subset. Thus, the current data indicate that the Cy-G-CSF mobilization regimen, while inducing a severe reduction in T-cell count, did not significantly affect the proportions of memory and naïve T cells. This is important considering that the memory T-cell repertoire in the autograft is critical to T-cell immunity reconstitution after high-dose chemotherapy (35) .
We then investigated T-cell activation. from that before Cy administration, using a Student t-test for pairs. ** Indicates that the mean value is significantly different (P ≤ .05) from that before Cy administration and from the nadir value at day 6, using a Student t-test for pairs. MM. * Indicates that the mean value is significantly different (P ≤ .05) from that before Cy administration, using a Student t-test for pairs. As standard deviations could be high due to interpatient variability, they were not shown. C, E. CD25 high (C) and CD25 low (E) cell counts determined before (day 0) and throughout Cy-G-CSF mobilization, at the time points described in Fig. 1 , for 14 patients with MM.
Data of individual patients are represented with specific symbol. Black horizontal lines denote mean values at each time point. * Indicates that the mean value is significantly different (P ≤ .01) from that before Cy administration (day 0), using a Student t-test for pairs. *** Indicates that the mean value is not different from that before Cy administration but is different (P ≤ .05) from the nadir value at day 6, using a Student t-test for pairs. 
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+ T-cell subsets from leukapheresis product (A) or PBMCs harvested before Cy-G-CSF treatment (B) were purified as described in Fig. 5 Relative GITR expression A B
